Compugen Cuts Q3 Spending, Loss on No Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen today reported that its third quarter net loss fell 44 percent as the firm cut its R&D and SG&A spending.

The Israeli company reported no revenues for the three-month period ended Sept. 30, compared with revenues of $6,000 for the third quarter of 2008.

Compugen's net loss decreased to $1.9 million, or $.06 per share, from $3.3 million, or $.12 per share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.